Table 1.
The characteristics of included RCTs in the meta-analysis.
| References | Case (I/C) | Gender (M/F) | Age (I/C) (years) | Stroke type | Intervention/ control | Dose (mg/d) | Durance | Outcome | Multicenter | Study design |
|---|---|---|---|---|---|---|---|---|---|---|
| Asadollahi et al. (20) | 60 (30/30) | 33/27 | 60.2 ± 8.52/61.7 ± 9.6 | Ischemic stroke | Fluoxetine/placebo | 20 | 90d | (1), (6), (7) | N | RCT |
| Asadollahi et al. (20) | 60 (30/30) | 35/25 | 58.7 ± 8.56/61.7 ± 9.6 | Ischemic stroke | Citalopram/placebo | 20 | 90d | (1), (6), (7) | N | RCT |
| Chollet et al. (4) | 118 (59/59) | 72/46 | 66.4 ± 11.7/62.9 ± 13.4 | Ischemic stroke | Fluoxetine/placebo | 20 | 90d | (1), (3), (5), (6), (7) | Y | RCT |
| FOCUS Trial Collaboration (5) | 3,127 (1,564/1,563) | 1,922/1,205 | 71.2 ± 12.4/71.5 ± 12.1 | Intracerebral hemorrhage or ischaemic stroke | Fluoxetine/placebo | 20 | 6 months | (5), (6), (7) | Y | RCT |
| Kraglund et al. (21) | 642 (319/323) | 421/221 | 68 ± 13/68 ± 13 | Ischemic stroke | Citalopram/placebo | 20 | 6 months | (4), (5), (6), (7) | Y | RCT |
| Affinity Trial Collaboration (6) | 1,280 (642/638) | 804/476 | 63.5 ± 12.5/64.6 ± 12.2 | Intracerebral hemorrhage or ischaemic stroke | Fluoxetine/placebo | 20 | 6 months | (5), (6), (7) | Y | RCT |
| Kim et al. (22) | 478 (241/237) | – | – | Intracerebral hemorrhage or ischaemic stroke | Escitalopram/placebo | 10 | 12 weeks | (2), (3), (4), (6), (7) | Y | RCT |
| Effects Trial Collaboration (8) | 1,500 (750/750) | 925/575 | 70.6 ± 11.3/71.0 ± 10.5 | Intracerebral hemorrhage or ischaemic stroke | Fluoxetine/placebo | 20 | 6 months | (3), (5), (6), (7) | Y | RCT |
| Marquez-Romero et al. (23) | 32 (15/17) | 15/15 | – | Intracerebral hemorrhage | Fluoxetine/placebo | 20 | 90d | (1), (2), (3), (5), (6), (7) | Y | RCT |
| Savadi Oskouie et al. (24) | 144 (72/72) | – | – | Ischemic stroke | Citalopram/placebo | 20 | 90d | (5), (6), (7) | N | RCT |
RCTs, randomized controlled trials; I/C, intervention/control; M, male; F, female; Y, yes; N, no; (1) Fugl-Meyer Motor Scale (FMMS) score; (2) Barthel Index (BI) score; (3) National Institutes of Health Stroke Scale (NIHSS) score; (4) modified Rankin Scale (mRS) score; (5) the proportion of patients with a mRS score of 0–2; (6) total withdrawal rate; (7) the incidence of adverse events (AEs).